mito-extra® - medac GmbH
mito-extra® - medac GmbH
mito-extra® - medac GmbH
Erfolgreiche ePaper selbst erstellen
Machen Sie aus Ihren PDF Publikationen ein blätterbares Flipbook mit unserer einzigartigen Google optimierten e-Paper Software.
54<br />
14 STICHWORTVERZEICHNIS<br />
A<br />
B<br />
C<br />
D<br />
E<br />
F<br />
G<br />
H<br />
Seitenzahl<br />
Adhäsion ........................................................... 22, 23, 24, 35<br />
Adriamycin ......................................................................... 07<br />
Alkylantien .......................................................................... 18<br />
Antitumorantibiotika ............................................................ 04<br />
Applikation ............................................................ 4, 9, 20, 51<br />
BCG ............................. 20, 28, 32, 34, 36, 37, 38, 39, 40, 41,<br />
43, 44, 45, 46, 47, 48, 49, 51, 52, 53<br />
Bioreduktive Alkylierung ...................................................... 14<br />
Blasenwand ............................................................ 18, 23, 27<br />
Chemocystitis ............................................................... 36, 37<br />
CIS ................................ 24, 25, 38, 39, 40, 41, 42, 46, 49, 51<br />
Connaught .......................................................................... 38<br />
DNA .............................................................. 5, 14, 15, 16, 18<br />
Doxorubicin .............................. 6, 7, 23, 24, 33, 35, 36, 37, 53<br />
Dwell-time ........................................................... 7, 18, 19, 52<br />
EMDA ..................................................................... 50, 51, 52<br />
Epirubicin ...................................................................... 24, 37<br />
Erhaltungstherapie .. 20, 25, 26, 30, 31, 32, 33, 39, 43, 46, 51, 53<br />
Fibrinbelag ........................................................................ 6, 7<br />
Frühinstillation .. 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 53<br />
G1 ................................. 15, 32, 34, 36, 38, 41, 46, 47, 49, 50<br />
Geschlossenes System ................................................... 9, 10<br />
Hämaturie ........................................................................... 44<br />
Hämorrhagisch ................................................................... 05<br />
Haltbarkeit ......................................................................... 8, 9<br />
High risk .................. 19, 20, 26, 28, 33, 38, 43, 44, 48, 49, 50<br />
Hyperthermie ...................................................................... 50
Change language